In:
Lung Cancer Management, Future Medicine Ltd, Vol. 4, No. 3 ( 2015-07), p. 113-115
Abstract:
David J Stewart returned to Ottawa from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) in 2011 to assume the position of Head of the Division of Medical Oncology at The Ottawa Hospital and the University of Ottawa. He received his MD degree from Queen's University, Kingston, followed by training in Internal Medicine at McGill University and in medical oncology in the Department of Developmental Therapeutics at the UT MD Anderson Cancer Center. He first moved from MD Anderson to the University of Ottawa and the Cancer Care Ontario Ottawa Regional Cancer Center in 1980, and served as Chief of Medical Oncology at the Ottawa Civic Hospital from 1989 to 1999. He returned to the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center from 2003 to 2011 where he served as Chief of the Section of Experimental Therapeutics (2003–2005), Chair Ad Interim (2005), Deputy Chair (2006–2009) and Director of Translational Research (2009–2011). He was also the Principle Investigator of MD Anderson’ Phase II N01 contract with the National Cancer Institute, and was the clinical leader of a number of other federally funded translational research project. He has more than 300 peer-reviewed publications, with a research focus on Phase I and II trials of new anticancer agents, translational research and resistance to anticancer agents. He also has a major interest in and concern for issues impeding cancer clinical research, with publications that have included (among others): Cancer: the road to Amiens (J. Clin. Oncol. 27(3), 328–33 [2009] ); Equipoise lost: ethics, costs and the regulation of cancer clinical research (J. Clin. Oncol. 28(17), 2925–35 [2010]); Fool's gold, lost treasures and the randomized clinical trial (BMC Cancer 13(1), 193 [2013] ); and Redefining cancer: a new paradigm for better and faster treatment innovation (J. Popul. Ther. Clin. Pharmacol. 21(1), e56–e65 [2014]). His experience in both the American and Canadian healthcare systems has provided him a unique perspective on how common regulatory factors seriously impair access to effective new therapies and drive inordinately high clinical research costs in both countries.
Type of Medium:
Online Resource
ISSN:
1758-1966
,
1758-1974
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2015
detail.hit.zdb_id:
2669715-4
Permalink